TP53 and ovarian cancer: In addition to anti‐angiogenic activity, both broussonin A and B have anti‐proliferative and anti‐invasive activities against NSCLC and ovarian cancer cells concomitant with suppression of integrin β1 expression, independently of p53 levels.